Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Virtual-reality Induced Immune Modulation in Allergic Patients

22. juli 2026 opdateret af: Peter Jandus, University of Geneva, Switzerland

This study investigates whether immersive virtual reality (VR) exposure to allergen-related stimuli can modulate behavioural, neurophysiological, psychophysiological, and immune responses in adults with bee or wasp venom allergy.

The study consists of two parts. In Part 1, adults with documented bee or wasp venom allergy and healthy volunteers will undergo immersive VR exposure in a realistic picnic environment. All participants will first be exposed to a control condition involving virtual flies. They will then be randomly assigned to exposure to either virtual bees or wasps or a control condition involving virtual flies. During the VR sessions, behavioural responses, heart rate and heart-rate variability, skin conductance, pupil dilation, temperature, and electroencephalographic activity will be recorded. Blood samples will be collected before and after VR exposure to assess changes in basophil activation and other immunological markers.

In Part 2, patients receiving standard-of-care venom immunotherapy will be followed longitudinally. Blood samples will be collected before and during treatment to characterize immunological changes associated with venom desensitization. After approximately six months of venom immunotherapy, participants will undergo a further VR session involving either virtual bees or wasps or virtual flies. Behavioural, psychophysiological, neurophysiological, and immunological assessments will be repeated to determine whether venom immunotherapy reduces responses to virtual allergen-related stimuli.

The primary outcome is the change in basophil activation, measured as the percentage of CD63-positive circulating basophils. Secondary outcomes include changes in circulating type 2 innate lymphoid cells and regulatory T cells, serum IL-13 and tryptase concentrations, reaction times, cardiovascular and autonomic responses, pupil dilation, skin temperature, and electroencephalographic responses.

The study does not involve exposure to real insects or venom as part of the investigational VR procedure. Its aim is to improve understanding of brain-immune interactions in allergy and to provide preliminary evidence for the potential future use of VR-based approaches alongside conventional allergy treatment.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

81

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria

  • Age 18 years or older.
  • Able to understand the participant information and provide written informed consent.
  • Willing and able to comply with all study procedures.

Part 1 - Healthy volunteers

  • No known bee or wasp venom allergy.
  • No current allergen immunotherapy or monoclonal antibody treatment.
  • No known active allergic, autoimmune, inflammatory, or immunodeficiency disorder requiring systemic treatment.

Part 1 - Participants with bee or wasp venom allergy

  • Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up.
  • No ongoing venom immunotherapy at the time of inclusion in Part 1.
  • No current monoclonal antibody treatment or systemic immunosuppressive treatment at the time of testing.

Part 2 - Participants undergoing venom immunotherapy

  • Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up.
  • Planned initiation of or ongoing treatment with standard-of-care venom immunotherapy.

Exclusion Criteria

  • Absence of written informed consent.
  • Inability to understand the study information or provide informed consent.
  • Age younger than 18 years.
  • Current systemic immunosuppressive therapy.
  • Current monoclonal antibody treatment for an allergic, autoimmune, or inflammatory disease at the time of testing.
  • Ongoing allergen immunotherapy for allergies other than bee or wasp venom allergy.
  • Leukocyte count below 3.5 G/L.
  • Hemoglobin below approximately 120 g/L in women or below approximately 130 g/L in men.
  • Bee or wasp sting reaction within the previous 2 months.
  • Intolerance to virtual reality, as assessed during a preliminary interview

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part 1: Allergen-related VR exposure
Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual bees or wasps progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief stimulus is delivered to simulate a sting.
Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual flies progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief synchronized stimulus is delivered to simulate touch or tickling. In Part 1, this intervention is administered to all participants as the initial baseline exposure and is repeated in participants assigned to the control condition.
Sham-komparator: Part 1: Control VR exposure
Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual flies progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief synchronized stimulus is delivered to simulate touch or tickling. In Part 1, this intervention is administered to all participants as the initial baseline exposure and is repeated in participants assigned to the control condition.
Eksperimentel: Part 2: Allergen-related VR exposure during VIT
Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual bees or wasps progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief stimulus is delivered to simulate a sting.
Sham-komparator: Part 2: Control VR exposure during VIT
Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual flies progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief synchronized stimulus is delivered to simulate touch or tickling. In Part 1, this intervention is administered to all participants as the initial baseline exposure and is repeated in participants assigned to the control condition.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Change in Percentage of CD63-Positive Circulating Basophils Following Virtual-Reality Exposure in Part 1
Tidsramme: T0, 10 minutes after the initial fly exposure, to T2, 40 minutes after the second VR exposure; same study day
T0, 10 minutes after the initial fly exposure, to T2, 40 minutes after the second VR exposure; same study day
Change in Percentage of CD63-Positive Circulating Basophils During Venom Immunotherapy and Subsequent Virtual-Reality Exposure in Part 2
Tidsramme: Before initiation of venom immunotherapy at T0 to 40 minutes after VR exposure at approximately month 7 at T5
Before initiation of venom immunotherapy at T0 to 40 minutes after VR exposure at approximately month 7 at T5

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. oktober 2030

Studieafslutning (Anslået)

1. oktober 2030

Datoer for studieregistrering

Først indsendt

17. juli 2026

Først indsendt, der opfyldte QC-kriterier

22. juli 2026

Først opslået (Faktiske)

23. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • UNIGE-VR-ALLERGY-2026-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

The protocol states that raw individual-level results will not be shared with third parties and that study results will be presented only in aggregated, non-identifiable form.

This does not prevent publication of aggregate results or deposition of summary datasets that contain no participant-level information.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Hymenoptera giftallergi

Kliniske forsøg med Allergen-related immersive virtual reality exposure

Abonner